19 Results for "

dipeptide conjugates

" in MedChemExpress (MCE) Product Catalog:
Products (19)

19 Results for "dipeptide conjugates" in MCE Product Catalog:

97
97 Cited Publications
Cat. No.: HY-15575
CAS No.: 646502-53-6
Purity:  99.94%
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
loading...
    loading...
Cat. No.: HY-164729
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
loading...
    loading...
Cat. No.: HY-P99682
CAS No.: 1629760-28-6
Synonyms: hLIV22
Target:  

ADC Antibodies

Research Areas:  

Cancer

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .
loading...
    loading...
Cat. No.: HY-15575S
Purity:  97.56%
Synonyms: MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .
loading...
    loading...
Cat. No.: HY-W010162
CAS No.: 1948-31-8
Synonyms: L-Alanyl-L-alanine; Ala-Ala
H-Ala-Ala-OH is a substrate of human intestinal oligopeptide transporter (PEPT1/SLC15A1), with an IC50 of 0.25 mM and an EC50 of 0.08 mM against human PEPT1. When used as a dipeptide linker in antibody-drug conjugates (ADCs) loaded with glucocorticoid receptor regulator payloads, H-Ala-Ala-OH enables efficient intracellular payload release .
loading...
    loading...
Cat. No.: HY-171138
CAS No.: 1178887-17-6
Synonyms: SET0568
Research Areas:  

Cancer

Mal-VC-PAB-DMEA-PNU-159682 (SET0568) is an antibody-drug conjugate (ADC) drug-linker conjugate. Mal-VC-PAB-DMEA-PNU-159682 is generated by conjugating the potent anti-topoisomerase II inhibitor PNU-159682 (HY-16700) to the lysosomally cleavable dipeptide Mc-VC-PAB, and exhibits strong antitumor activity. Mal-VC-PAB-DMEA-PNU-159682 can be used to synthesize CD22-targeting ADCs, such as Anti-CD22-NMS249 (HY-164761). Mal-VC-PAB-DMEA-PNU-159682 is also applicable to the research of non-Hodgkin's lymphoma .
loading...
    loading...
Cat. No.: HY-W002304
CAS No.: 4042-36-8
(R)-5-Oxopyrrolidine-2-carboxylic acid is a cyclic derivative of D-glutamate, as well as a heterocyclic structural unit and a precursor of cyclic imino acids. (R)-5-Oxopyrrolidine-2-carboxylic acid acts as an intermediate in the synthesis of dipeptide hybrids with antibacterial activity and the synthesis of Δ-1-pyrroline-5-carboxylic acid (P5C). (R)-5-Oxopyrrolidine-2-carboxylic acid is applicable to research related to organic synthesis .
loading...
    loading...
Cat. No.: HY-42709
CAS No.: 24787-89-1
Synonyms: Carbobenzoxy-L-valyl-L-alanine
Research Areas:  

Cancer

Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .
loading...
    loading...
Cat. No.: HY-P99238
CAS No.: 2095467-30-2

Target:  

ADC Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .
loading...
    loading...
Cat. No.: HY-P5299
CAS No.: 114726-49-7
Research Areas:  

Others

Fmoc-Gly-Gly-OSu is a dipeptide linker intermediate composed of glycine residues, with its N-terminus protected by Fmoc and C-terminus activated by N-hydroxysuccinimide (OSu). Fmoc-Gly-Gly-OSu can be used for the synthesis of ADC linker .
loading...
    loading...
Cat. No.: HY-171572
Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .
loading...
    loading...
Cat. No.: HY-78932A
CAS No.: 2019182-02-4
Target:  

ADC Linkers

Research Areas:  

Cancer

Dap-NE hydrochloride is a dipeptide hydrochloride and a cleavable ADC Linker.Dap-NE hydrochloride can be used to connect Antibody and toxin molecules (Cytotoxin) to synthesize Antibody-Drug Conjugates (ADCs) .
loading...
    loading...
Cat. No.: HY-148495
Purity:  ≥90.0%
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Carnosine conjugated hyalyronate is a hyaluronic acid derivative functionalized with the dipeptide carnosine (Carnosine, Car) and has the ability to resist amyloid aggregation. Carnosine conjugated hyalyronate dissolves amyloid fibrils and reduces Aβ-induced toxicity in vitro. The effectiveness of Carnosine conjugated hyalyronate against amyloid aggregation is directly proportional to the Carnosine loading .
loading...
    loading...
Cat. No.: HY-P10775
Research Areas:  

Cancer

BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .
loading...
    loading...
Cat. No.: HY-141599
CAS No.: 1853239-04-9
Synonyms: ADCT 301
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .
loading...
    loading...
Cat. No.: HY-78931C
CAS No.: 3026595-14-9
Target:  

Drug Intermediate

Research Areas:  

Cancer

(S,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
loading...
    loading...
Cat. No.: HY-78931E
Target:  

Drug Intermediate

Research Areas:  

Cancer

(R,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
loading...
    loading...
Cat. No.: HY-78931F
Target:  

Drug Intermediate

Research Areas:  

Cancer

(R,S,S,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
loading...
    loading...
Cat. No.: HY-W002304R
CAS No.: 4042-36-8
(R)-5-Oxopyrrolidine-2-carboxylic acid (Standard) is the analytical standard of (R)-5-Oxopyrrolidine-2-carboxylic acid (HY-W002304). This product is intended for research and analytical applications. (R)-5-Oxopyrrolidine-2-carboxylic acid is a cyclic derivative of D-glutamate, as well as a heterocyclic structural unit and a precursor of cyclic imino acids. (R)-5-Oxopyrrolidine-2-carboxylic acid acts as an intermediate in the synthesis of dipeptide hybrids with antibacterial activity and the synthesis of Δ-1-pyrroline-5-carboxylic acid (P5C). (R)-5-Oxopyrrolidine-2-carboxylic acid is applicable to research related to organic synthesis .
loading...
    loading...
  • 1